[ad_1]
The “Investigation Report on China’s Omalizumab Market 2021-2025” report has been added to ResearchAndMarkets.com’s offering.
Omalizumab, developed by Novartis Europharm, is the only approved antibody designed to target and block immunoglobulin E (IgE).
The analyst predicts that with the increase in the number of indications, the sales of Omalizumab in China will continue to grow from 2021 to 2025.
China is one of the countries with the highest mortality rate of asthma in the world. In 2020, there were about 30 million asthma patients in China, which was 1.5 times higher than the number of patients in 2017 (20 million). Therefore, it can be speculated that the number of indications of Omalizumab in China will continue to grow and sales will increase accordingly.
Omalizumab is clinically more accurate and more effective than inhaled corticosteroids and long-acting inhaled ß2-adrenergic receptor agonists, especially for patients with moderate to severe asthma. Based on these therapeutic advantages, the market share of Omalizumab will increase in the future.
In addition, Omalizumab has only been approved for one indication in China, and 4 indications have been approved globally. Therefore, the number of approved indications for Omalizumab in China still has potential for growth. It can be predicted that its sales will continue to grow with the expansion of the market and the increase of the number of indications in the future.
At the end of 2017, the FDA…
Full story available on Benzinga.com
[ad_2]
Source link
